OTC Xyzal Sales Jump Helps Drive Sanofi Consumer Health Q2 Sales
French pharma reports OTC Xyzal sales up nearly 86% to $14.5m during latest quarter, providing driver for allergy/cough/cold segment of its consumer health business. Total consumer health revenues, including nutritional and personal care products, up 1.1% at a consent exchange rate to $1.3bn during the April-June period.
You may also be interested in...
Sanofi consumer health chief Alan Main says with the US the largest OTC drug market, a successful switch for Tamiflu, marketed in the US by Roche subsidiary Genentech, would support the firm's global strategy for expanding cough and cold remedy sales.
"You need to demonstrate to the best of your ability that you can't get there with just the Drug Facts label," says ONDP Director Theresa Michele during presentation on the FDA office' work over the past year at Consumer Healthcare Products Association's annual regulations and science conference.
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.